| Code | 8739B | ||||||||||
| MA number | 27/0125/16-S | ||||||||||
| Product Form: | tbl 112x1 mg (blis.OPA/Al/PVC/Al) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | STADA Arzneimittel AG, Germany | ||||||||||
| Therapeutic Class: | 27 - ANTIPARKINSONICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | blister OPA/Al/PVC/Al | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 18.03.2016 |
| SPC: |
SPC_Rasagiline Stada_03.2020.docx
|
| PIL: |
PIL_Rasagiline Stada_08.2023.pdf
|
| Safety feature | Yes |
| Data update: | 17.06.2020 |
